scPharmaceuticals Inc. (NASDAQ:SCPH) Given Average Recommendation of “Buy” by Brokerages

Shares of scPharmaceuticals Inc. (NASDAQ:SCPH – Get Rating) have been assigned an average recommendation of “Buy” from the six analysts that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $18.00.

A number of equities analysts have recently issued reports on the stock. Cowen assumed coverage on shares of scPharmaceuticals in a research report on Thursday, December 1st. They set an “outperform” rating and a $25.00 target price on the stock. SVB Leerink raised their target price on shares of scPharmaceuticals from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, January 27th. Finally, Cowen began coverage on shares of scPharmaceuticals in a research report on Thursday, December 1st. They issued an “outperform” rating and a $25.00 price objective on the stock.

Hedge Funds Weigh In On scPharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AIGH Capital Management LLC lifted its holdings in scPharmaceuticals by 236.9% in the fourth quarter. AIGH Capital Management LLC now owns 2,550,234 shares of the company’s stock valued at $18,285,000 after acquiring an additional 1,793,171 shares during the period. RA Capital Management L.P. acquired a new stake in scPharmaceuticals in the fourth quarter valued at $13,314,000. Millennium Management LLC lifted its holdings in scPharmaceuticals by 3,161.5% in the fourth quarter. Millennium Management LLC now owns 825,725 shares of the company’s stock valued at $5,920,000 after acquiring an additional 800,408 shares during the period. Worth Venture Partners LLC lifted its holdings in scPharmaceuticals by 4.7% in the first quarter. Worth Venture Partners LLC now owns 348,425 shares of the company’s stock valued at $1,979,000 after acquiring an additional 15,778 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in scPharmaceuticals by 54.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 215,238 shares of the company’s stock valued at $1,543,000 after acquiring an additional 76,119 shares during the period. 53.90% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Trading Down 1.0 %

Shares of SCPH opened at $6.82 on Friday. The firm has a market cap of $187.07 million, a PE ratio of -5.37 and a beta of 0.22. The company’s 50 day simple moving average is $7.19 and its 200-day simple moving average is $6.34. scPharmaceuticals has a 12-month low of $3.68 and a 12-month high of $10.38.

About scPharmaceuticals

(Get Rating)

scPharmaceuticals, Inc engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting.